LANXESS plans to expand capacity for Oxone monopersulfate - a main active ingredient for disinfectants
Significant increase in demand due to African swine fever and corona pandemic
Due to the continuous strong demand for disinfectants, specialty chemicals company LANXESS is planning to expand its production capacity for Oxone monopersulfate by around 50 percent. To this end, the company intends to invest a lower double-digit million euro sum in its production facility in Memphis, USA.

LANXESS
LANXESS uses Oxone monopersulfate as the main active ingredient in many of its Virkon and Rely+On disinfection products. Demand for these products has increased significantly in recent months due to, amongst others, the outbreak of African swine fever as well as the corona pandemic. The company also sells Oxone as a powerful oxidizing agent for numerous other applications. The capacity expansion is expected to be completed in the second half of 2022.
“Disinfection products are important growth drivers in our highly profitable Consumer Protection segment. We expect a sustainable high level of demand even after the corona pandemic,” said Matthias Zachert, Chairman of the LANXESS Board of Management.
Michael Schäfer, head of LANXESS' Material Protection Products business unit, added: “We are also seeing a growing demand for Oxone in the water treatment sector as well as from the electronics and paper industries. We want to meet this demand by expanding our production capacity.”
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Northern_Norway_Pharmaceutical_Trust

Cell culture: The opportunities and the challenges - The promise of cell culture is accelerating demand, and emphasising the challenges, of this process
Crucell Teams up with ACE BioSciences and Harvard to Accelerate Bacterial Antibody Program
St_John_Ambulance_in_England_and_Wales
Harold_Ridley_(ophthalmologist)
Henry_Suter
